Clinical research on relationship of IL-8, VEGF-A and VEGFR-2 of recurrent advanced gastrointestinal tumor and the efficacy and prognosis of Apatinib.
Latest Information Update: 08 Sep 2016
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- 08 Sep 2016 New trial record